8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 23, 2026·SEC
Context Therapeutics Inc.(CNTX)Earnings, Financials & Key Ratios
CNTX•NASDAQ
Price updated Jun 19, 2026
AboutContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$0
- EBITDA-$40M-32.7%
- Net Income-$36M-35.2%
- EPS (Diluted)-0.38+17.4%
- ROE-46.39%+7.0%
CNTX Key Insights
Context Therapeutics Inc. (CNTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 62.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CNTX Price & Volume
Context Therapeutics Inc. (CNTX) stock price & volume — 10-year historical chart
Loading chart...
CNTX Growth Metrics
Context Therapeutics Inc. (CNTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-45.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-14.8%
Return on Capital
10 Years-61.01%
5 Years-61.01%
3 Years-71.43%
Last Year-50.95%
CNTX Recent Earnings
Context Therapeutics Inc. (CNTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.09+25.0%
$0.12
Rev
—
—
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.14-27.3%
$0.11
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.14-27.3%
$0.11
Rev
—
$1M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.10-11.1%
$0.09
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.09vs $0.12+25.0% | — |
| Q2 2026 | Mar 23, 2026 | $0.14vs $0.11-27.3% | — |
| Q2 2026 | Mar 19, 2026 | $0.14vs $0.11-27.3% | —vs $1M |
| Q4 2025 | Nov 5, 2025 | $0.10vs $0.09-11.1% | — |
Based on last 12 quarters of dataView full earnings history →
CNTX Peer Comparison
Context Therapeutics Inc. (CNTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ONCO | 593.27K | 0.94 | -0.20 | -67.7% | -13.2% | -105.46% | 0.00 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PRME | 583.39M | 3.23 | -2.39 | 55.28% | -49.18% | -188.82% | 0.96 |
Compare CNTX vs Peers
Context Therapeutics Inc. (CNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CNTX Income Statement
Context Therapeutics Inc. (CNTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.07K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -4.07K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - |
Operating Expenses | 5.38M | 2.57M | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M | 43.51M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 2.96M | 930.67K | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M | 8.11M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 2.41M | 1.64M | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M | 35.41M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 3.09M | 500K | 0 | 0 | 0 | 0 |
Operating Income | -5.38M▲ 0% | -2.57M▲ 52.2% | -10.53M▼ 309.2% | -15.38M▼ 46.1% | -25.07M▼ 63.0% | -29.92M▼ 19.3% | -39.7M▼ 32.7% | -43.52M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 52.17% | -309.25% | -46.13% | -63.01% | -19.35% | -32.68% | - |
EBITDA | -5.38M | -2.57M | -10.39M | -15.37M | -25.06M | -29.91M | -39.69M | -43.51M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | 52.17% | -304.07% | -47.91% | -63.03% | -19.36% | -32.67% | -37.6% |
D&A (Non-Cash Add-back) | 0 | 0 | 0 | 9.27K | 12.04K | 10.88K | 16.25K | 12.2K |
EBIT | -5.28M | -2.57M | -10.39M | -14.88M | -25.07M | -29.92M | -39.7M | -33.26M |
Net Interest Income | -1.1M | -661K | -64.17K | 0 | 1.16M | 3.2M | 3.38M | 2.42M |
Interest Income | 1.1K | 661 | 64 | 547.27K | 1.16M | 3.2M | 3.38M | 2.94M |
Interest Expense | 1.1M | 661.22K | 64.24K | 547.27K | 0 | 0 | 0 | 0 |
Other Income/Expense | -1.01M | 9.22M | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M | 3.29M |
Pretax Income | -6.38M▲ 0% | 6.64M▲ 204.1% | -10.46M▼ 257.4% | -14.84M▼ 41.9% | -23.96M▼ 61.5% | -26.73M▼ 11.5% | -36.12M▼ 35.2% | -40.23M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -6.38M▲ 0% | 6.64M▲ 204.1% | -10.46M▼ 257.4% | -14.84M▼ 41.9% | -23.96M▼ 61.5% | -26.73M▼ 11.5% | -36.12M▼ 35.2% | -40.23M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | 204.07% | -257.39% | -41.88% | -61.53% | -11.52% | -35.17% | -45.57% |
Net Income (Continuing) | -6.38M | 6.64M | -10.46M | -14.84M | -23.96M | -26.73M | -36.12M | -40.23M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.68▲ 0% | -0.80▼ 17.6% | -3.69▼ 361.2% | -0.93▲ 74.8% | -1.50▼ 61.3% | -0.46▲ 69.3% | -0.38▲ 17.4% | -0.42▲ 0% |
EPS Growth % | - | -17.65% | -361.25% | 74.8% | -61.29% | 69.33% | 17.39% | -14.8% |
EPS (Basic) | -0.68 | 0.61 | -3.69 | -0.93 | -1.50 | -0.46 | -0.38 | - |
Diluted Shares Outstanding | 10.96M | 10.96M | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M | 95.18M |
Basic Shares Outstanding | 10.96M | 10.96M | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M | 95.18M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CNTX Balance Sheet
Context Therapeutics Inc. (CNTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 239.61K | 349.71K | 51.26M | 37.85M | 16.05M | 97.9M | 68.35M | 58.52M |
Cash & Short-Term Investments | 226.6K | 341.04K | 49.64M | 35.5M | 14.45M | 94.43M | 66M | 54.53M |
Cash Only | 226.6K | 341.04K | 49.64M | 35.5M | 14.45M | 94.43M | 66M | 54.53M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 2.36M | 1.6M | 3.47M | 2.36M | 3.99M |
Total Non-Current Assets | 33.94K | 117.63K | 50.39K | 112.28K | 15.52K | 230.78K | 140.07K | 342.28K |
Property, Plant & Equipment | 0 | 0 | 0 | 79.53K | 15.52K | 230.78K | 140.07K | 342.28K |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 50.39K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 33.94K | 117.63K | 0 | 32.75K | 0 | 0 | 0 | 0 |
Total Assets | 273.55K▲ 0% | 467.34K▲ 70.8% | 51.31M▲ 10878.2% | 37.97M▼ 26.0% | 16.06M▼ 57.7% | 98.13M▲ 510.9% | 68.49M▼ 30.2% | 58.86M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 70.84% | 10878.25% | -26% | -57.69% | 510.9% | -30.2% | -90.26% |
Total Current Liabilities | 24.11M | 9.55M | 3.03M | 3.21M | 4.19M | 2.75M | 8.02M | 6.53M |
Accounts Payable | 2.07M | 2.71M | 1.83M | 936.33K | 2.38M | 1.45M | 2.53M | 2.47M |
Days Payables Outstanding | - | - | - | - | - | - | - | 227.01K |
Short-Term Debt | 21.84M | 5.88M | 0 | 0 | 0 | 0 | 112.06K | 160.06K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 85.53K | 853.51K | 661.3K | 941.7K | 5.38M | 3.91M |
Current Ratio | 0.01x | 0.04x | 16.90x | 11.80x | 3.83x | 35.62x | 8.52x | 8.96x |
Quick Ratio | 0.01x | 0.04x | 16.90x | 11.80x | 3.83x | 35.62x | 8.52x | 8.96x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 126K | 7.84M | 0 | 0 | 0 | 112.06K | 0 | 122.37K |
Long-Term Debt | 0 | 69.04K | 0 | 0 | 0 | 0 | 0 | 122.37K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 112.06K | 0 | 73.55K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 126K | 7.77M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 24.23M | 17.39M | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M | 6.66M |
Total Debt | 21.84M | 5.95M | 0 | 55.08K | 0 | 219.38K | 112.06K | 282.42K |
Net Debt | 21.62M | 5.61M | -49.64M | -35.44M | -14.45M | -94.21M | -65.88M | -54.25M |
Debt / Equity | - | - | - | 0.00x | - | 0.00x | 0.00x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 1.25x |
Interest Coverage | -4.80x | -3.89x | -161.78x | -27.19x | - | - | - | - |
Total Equity | -23.96M▲ 0% | -16.92M▲ 29.4% | 48.27M▲ 385.3% | 34.76M▼ 28.0% | 11.87M▼ 65.8% | 95.27M▲ 702.5% | 60.47M▼ 36.5% | 52.2M▲ 0% |
Equity Growth % | - | 29.38% | 385.28% | -28% | -65.85% | 702.51% | -36.52% | -110.24% |
Book Value per Share | -2.19 | -1.54 | 17.03 | 2.18 | 0.74 | 1.63 | 0.64 | 0.55 |
Total Shareholders' Equity | -23.96M | -16.92M | 48.27M | 34.76M | 11.87M | 95.27M | 60.47M | 52.2M |
Common Stock | 324 | 332 | 15.97K | 15.97K | 15.97K | 89.7K | 91.88K | 91.88K |
Retained Earnings | -25.44M | -18.8M | -29.25M | -44.09M | -68.05M | -94.78M | -130.9M | -139.58M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CNTX Cash Flow Statement
Context Therapeutics Inc. (CNTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.84M | -1.03M | -8.8M | -13.55M | -21.05M | -14.56M | -26.39M | -32.79M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | 63.52% | -750.5% | -53.98% | -55.34% | 30.84% | -81.27% | -523.72% |
Net Income | -6.38M | 6.64M | -10.46M | -14.84M | -23.96M | -26.73M | -36.12M | -40.23M |
Depreciation & Amortization | 0 | 0 | 0 | 9.27K | 12.04K | 10.88K | 16.25K | 48.3K |
Stock-Based Compensation | 775.25K | 219.25K | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M | 1.04M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.21M | -9.22M | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M | 2.49M |
Working Capital Changes | 561.79K | 1.32M | -2.22M | -277.52K | 1.78M | -3.48M | 6.28M | 3.86M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 505.41K | 556.27K | -866.01K | -787.89K | 1.45M | -946K | 1.1M | 1.46M |
Cash from Investing | 0 | 0 | -250K | -536.84K | 0 | -14.76M | -2.03M | -2.04M |
Capital Expenditures | 0 | 0 | -250K | -536.84K | 0 | -7.32K | -33.95K | -2.04M |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | -14.75M | -2M | 0 |
Cash from Financing | 1.96M | 1.15M | 58.39M | -102.07K | 0 | 109.29M | -15.27K | 0 |
Debt Issued (Net) | 1.96M | 149.05K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 1M | 58.39M | -102.07K | 0 | 109.29M | -15.27K | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | -878.69K▲ 0% | 114.43K▲ 113.0% | 49.34M▲ 43020.5% | -14.14M▼ 128.7% | -21.05M▼ 48.9% | 79.98M▲ 480.0% | -28.43M▼ 135.6% | -34.82M▲ 0% |
Free Cash Flow | -2.84M▲ 0% | -1.03M▲ 63.5% | -9.05M▼ 774.7% | -14.09M▼ 55.7% | -21.05M▼ 49.4% | -29.31M▼ 39.3% | -26.42M▲ 9.9% | -32.82M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | 63.52% | -774.67% | -55.66% | -49.42% | -39.27% | 9.87% | -115.02% |
FCF per Share | -0.26 | -0.09 | -3.19 | -0.88 | -1.32 | -0.50 | -0.28 | -0.34 |
FCF Conversion (FCF/Net Income) | 0.44x | -0.16x | 0.84x | 0.91x | 0.88x | 0.54x | 0.73x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CNTX Key Ratios
Context Therapeutics Inc. (CNTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -66.71% | -35.74% | -102.79% | -49.89% | -46.39% | -59.95% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | 1098.69% |
Debt / Equity | - | - | 0.00x | - | 0.00x | 0.00x | 0.01x |
Interest Coverage | -3.89x | -161.78x | -27.19x | - | - | - | - |
FCF Conversion | -0.16x | 0.84x | 0.91x | 0.88x | 0.54x | 0.73x | 0.82x |
Related:CNTX Dividend History·CNTX Revenue History·CNTX Price History·CNTX P/E History·CNTX Financial Ratios·CNTX Institutional Holders
CNTX SEC Filings & Documents
Context Therapeutics Inc. (CNTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CNTX Frequently Asked Questions
Context Therapeutics Inc. (CNTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Context Therapeutics Inc. (CNTX) grew revenue by 0.0% over the past year. Growth has been modest.
Context Therapeutics Inc. (CNTX) reported a net loss of $40.2M for fiscal year 2025.
Dividend & Returns
Context Therapeutics Inc. (CNTX) has a return on equity (ROE) of -46.4%. Negative ROE indicates the company is unprofitable.
Context Therapeutics Inc. (CNTX) had negative free cash flow of $32.8M in fiscal year 2025, likely due to heavy capital investments.